Both Endocyte and Merck have much to gain from potential $1bn cancer alliance
This article was originally published in Scrip
In a $1 billion partnership for Endocyte's lead folate-targeting cancer drug candidate and its companion diagnostic, the West Lafayette, Indiana-based biopharmaceutical company gets money to advance more of its early stage programmes and Merck gets access to an oncology therapeutic that may have a better chance of winning regulatory approval than its competitors.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.